In notable advances within oncology and computational biology, multiple teams have developed and applied machine learning tools to refine cancer diagnostics and prognostication. A Chinese research group introduced OncoChat, an AI method integrating genomic mutations and clinical data to predict cancer primary sites with improved accuracy, including cancers of unknown primary origin. Additionally, deep learning-based models like GPT-4 have demonstrated potential in enhancing decision-making for prostate biopsies. These AI-driven tools promise more precise treatments and personalized medicine approaches, improving patient outcomes across diverse cancer types.